Back to News
Market Impact: 0.2
Tiziana Signs MOU With KAIMRC To Advance Foralumab MS Trials; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Tiziana Life Sciences signed a memorandum of understanding with King Abdullah International Medical Research Center (KAIMRC) related to its immunomodulation-therapy development efforts. The announcement supports external clinical and research collaboration around Tiziana's lead intranasal foralumab candidate, though no financial terms, trial details, or commercialization commitments were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
TLSA0.45
More News
- Binance seeks to shore up confidence after record $6.3 billion heist
- Why is Alstom stock down 27% today?
- Alstom shares sink 28% after outlook cut on Coradia Max execution issues
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Binance sees outflows stabilising as exchange returns online after $6.3 billion heist
- Apollo launches $11 billion private credit platform, backed by Abu Dhabi
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- AI for Investment Thesis Validation: A Claim-Ledger Method
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)